P53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 318-330

  Marcel, Virginie ^a,b   Ghayad, SandraE ^a,b   Belin, Stéphane ^a,b   Therizols, Gabriel ^a,b   Morel, Anne Pierre ^a,b   Solano Gonzàlez, Eduardo ^c   Vendrell, JulieA ^a,b,d   Hacot, Sabine ^a,b   Mertani, HichemC ^a,b   Albaret, MarieAlexandra ^a,b   Bourdon, Jean Christophe ^d   Jordan, Lee ^e   Thompson, Alastair ^d   Tafer, Yasmine ^a,b   Cong, Rong ^f   Bouvet, Philippe ^f   Saurin, Jean Christophe ^a,b,g   Catez, Frédéric ^a,b   Prats, Anne Catherine ^c   Puisieux, Alain ^a,b   Diaz, Jean Jacques ^a,b   more..

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c University Hospital of Toulouse   (France)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f UNIVERSITÉ DE LYON   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FIBRILLARIN; MESSENGER RNA; METHYLTRANSFERASE; PROTEIN; PROTEIN P53; RIBOSOME RNA;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; INTERNAL RIBOSOME ENTRY SITE; METHYLATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIBOSOME; TRANSLATION INITIATION; TUMOR SUPPRESSOR GENE;

EID: 84883634636     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.013     Document Type: Article

References (57)

1. Anger A.M., Armache J.P., Berninghausen O., Habeck M., Subklewe M., Wilson D.N., Beckmann R. Structures of the human and Drosophila 80S ribosome. Nature 2013, 497:80-85.
2. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., Rao P.H., Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008, 456:971-975.
3. Bashan A., Yonath A. Correlating ribosome function with high-resolution structures. Trends Microbiol. 2008, 16:326-335.
4. Basu A., Das P., Chaudhuri S., Bevilacqua E., Andrews J., Barik S., Hatzoglou M., Komar A.A., Mazumder B. Requirement of rRNA methylation for 80S ribosome assembly on a cohort of cellular internal ribosome entry sites. Mol. Cell. Biol. 2011, 31:4482-4499.
5. Baudin-Baillieu A., Fabret C., Liang X.-H., Piekna-Przybylska D., Fournier M.J., Rousset J.-P. Nucleotide modifications in three functionally important regions of the Saccharomyces cerevisiae ribosome affect translation accuracy. Nucleic Acids Res. 2009, 37:7665-7677.
6. Baxter-Roshek J.L., Petrov A.N., Dinman J.D. Optimization of ribosome structure and function by rRNA base modification. PLoS ONE 2007, 2:e174.
7. Belin S., Beghin A., Solano-Gonzàlez E., Bezin L., Brunet-Manquat S., Textoris J., Prats A.-C., Mertani H.C., Dumontet C., Diaz J.-J. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS ONE 2009, 4:e7147.
8. Belin S., Kindbeiter K., Hacot S., Albaret M.A., Roca-Martinez J.X., Thérizols G., Grosso O., Diaz J.-J. Uncoupling ribosome biogenesis regulation from RNA polymerase I activity during herpes simplex virus type 1 infection. RNA 2010, 16:131-140.
9. Blanchard S.C., Puglisi J.D. Solution structure of the A loop of 23S ribosomal RNA. Proc. Natl. Acad. Sci. USA 2001, 98:3720-3725.
10. Bourdon J.-C., Khoury M.P., Diot A., Baker L., Fernandes K., Aoubala M., Quinlan P., Purdie C.A., Jordan L.B., Prats A.-C., et al. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 2011, 13:R7.
11. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
12. Bywater M.J., Poortinga G., Sanij E., Hein N., Peck A., Cullinane C., Wall M., Cluse L., Drygin D., Anderes K., et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012, 22:51-65.
13. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
14. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., Frisch M., Bayerlein M., Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
15. Cech T.R. Structural biology. The ribosome is a ribozyme. Science 2000, 289:878-879.
16. Chaudhuri S., Vyas K., Kapasi P., Komar A.A., Dinman J.D., Barik S., Mazumder B. Human ribosomal protein L13a is dispensable for canonical ribosome function but indispensable for efficient rRNA methylation. RNA 2007, 13:2224-2237.
17. Choi Y.W., Kim Y.W., Bae S.M., Kwak S.Y., Chun H.J., Tong S.Y., Lee H.N., Shin J.C., Kim K.T., Kim Y.J., Ahn W.S. Identification of differentially expressed genes using annealing control primer-based GeneFishing in human squamous cell cervical carcinoma. Clin. Oncol. (RColl Radiol) 2007, 19:308-318.
18. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
19. Demeshkina N., Jenner L., Westhof E., Yusupov M., Yusupova G. A new understanding of the decoding principle on the ribosome. Nature 2012, 484:256-259.
20. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001, 15:50-65.
21. Galy B., Créancier L., Zanibellato C., Prats A.-C., Prats H. Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism. Oncogene 2001, 20:1669-1677.
22. Ghayad S.E., Vendrell J.A., Bieche I., Spyratos F., Dumontet C., Treilleux I., Lidereau R., Cohen P.A. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J.Mol. Endocrinol. 2009, 42:87-103.
23. Giraud S., Greco A., Brink M., Diaz J.-J., Delafontaine P. Translation initiation of the insulin-like growth factor I receptor mRNA is mediated by an internal ribosome entry site. J.Biol. Chem. 2001, 276:5668-5675.
24. Györffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
25. Henras A.K., Soudet J., Gérus M., Lebaron S., Caizergues-Ferrer M., Mougin A., Henry Y. The post-transcriptional steps of eukaryotic ribosome biogenesis. Cell. Mol. Life Sci. 2008, 65:2334-2359.
26. Higa-Nakamine S., Suzuki T., Uechi T., Chakraborty A., Nakajima Y., Nakamura M., Hirano N., Suzuki T., Kenmochi N. Loss of ribosomal RNA modification causes developmental defects in zebrafish. Nucleic Acids Res. 2012, 40:391-398.
27. King T.H., Liu B., McCully R.R., Fournier M.J. Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol. Cell 2003, 11:425-435.
28. Koh C.M., Gurel B., Sutcliffe S., Aryee M.J., Schultz D., Iwata T., Uemura M., Zeller K.I., Anele U., Zheng Q., et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am. J. Pathol. 2011, 178:1824-1834.
29. Komar A.A., Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 2011, 10:229-240.
30. Krastev D.B., Slabicki M., Paszkowski-Rogacz M., Hubner N.C., Junqueira M., Shevchenko A., Mann M., Neugebauer K.M., Buchholz F. A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Nat. Cell Biol. 2011, 13:809-818.
31. Liang X.H., Liu Q., Fournier M.J. Loss of rRNA modifications in the decoding center of the ribosome impairs translation and strongly delays pre-rRNA processing. RNA 2009, 15:1716-1728.
32. Maden B.E. Locations of methyl groups in 28S rRNA of Xenopus laevis and man. Clustering in the conserved core of molecule. J.Mol. Biol. 1988, 201:289-314.
33. Menendez D., Inga A., Resnick M.A. The expanding universe of p53 targets. Nat. Rev. Cancer 2009, 9:724-737.
34. Meng Z., Jackson N.L., Shcherbakov O.D., Choi H., Blume S.W. The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop. J.Cell. Biochem. 2010, 110:531-544.
35. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
36. Montanaro L., Calienni M., Ceccarelli C., Santini D., Taffurelli M., Pileri S., Treré D., Derenzini M. Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell. Oncol. 2008, 30:483-490.
37. Mulvihill M.J., Cooke A., Rosenfeld-Franklin M., Buck E., Foreman K., Landfair D., O'Connor M., Pirritt C., Sun Y., Yao Y., et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009, 1:1153-1171.
38. Newton K., Petfalski E., Tollervey D., Cáceres J.F. Fibrillarin is essential for early development and required for accumulation of an intron-encoded small nucleolar RNA in the mouse. Mol. Cell. Biol. 2003, 23:8519-8527.
39. Nikulenkov F., Spinnler C., Li H., Tonelli C., Shi Y., Turunen M., Kivioja T., Ignatiev I., Kel A., Taipale J., Selivanova G. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012, 19:1992-2002.
40. Olivier M., Langerød A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bièche I., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 2006, 12:1157-1167.
41. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
42. Puglisi J.D. Resolving the elegant architecture of the ribosome. Mol. Cell 2009, 36:720-723.
43. Ruggero D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 2013, 5. a012336-a012336.
44. Ruggero D., Grisendi S., Piazza F., Rego E., Mari F., Rao P.H., Cordon-Cardo C., Pandolfi P.P. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 299:259-262.
45. Sabatier R., Finetti P., Cervera N., Lambaudie E., Esterni B., Mamessier E., Tallet A., Chabannon C., Extra J.M., Jacquemier J., et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res. Treat. 2011, 126:407-420.
46. Sakuma K., Aoki M., Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. USA 2012, 109:7776-7781.
47. Sbisà E., Catalano D., Grillo G., Licciulli F., Turi A., Liuni S., Pesole G., De Grassi A., Caratozzolo M.F., D'Erchia A.M., et al. p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining insilico prediction and microarray data. BMC Bioinformatics 2007, 8(Suppl 1):S20.
48. Spahn C.M., Jan E., Mulder A., Grassucci R.A., Sarnow P., Frank J. Cryo-EM visualization of a viral internal ribosome entry site bound to human ribosomes: the IRES functions as an RNA-based translation factor. Cell 2004, 118:465-475.
49. Su H., Xu T., Ganapathy S., Shadfan M., Long M., Huang T.H., Thompson I., Yuan Z.M. Elevated snoRNA biogenesis is essential in breast cancer. Oncogene 2013, Published online April 1, 2013. 10.1038/onc.2013.89.
50. Tollervey D., Lehtonen H., Jansen R., Kern H., Hurt E.C. Temperature-sensitive mutations demonstrate roles for yeast fibrillarin in pre-rRNA processing, pre-rRNA methylation, and ribosome assembly. Cell 1993, 72:443-457.
51. Troester M.A., Herschkowitz J.I., Oh D.S., He X., Hoadley K.A., Barbier C.S., Perou C.M. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276.
52. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
53. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., Van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005, 65:9155-9158.
54. Xue S., Barna M. Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nat. Rev. Mol. Cell Biol. 2012, 13:355-369.
55. Yonath A. Large facilities and the evolving ribosome, the cellular machine for genetic-code translation. J.R. Soc. Interface 2009, 6(Suppl 5):S575-S585.
56. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
57. Zhai W., Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 2000, 20:5930-5938.